Perjeta 420mg/14ml (Pertuzumab Vials) 420mg/14ml

Perjeta 420mg/14ml is an anti-HER2 therapy used in the treatment of HER2-positive breast cancer. It is indicated for both metastatic and early-stage breast cancer in combination with other medications.

• HER2-positive metastatic breast cancer: Used in combination with trastuzumab and docetaxel for patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
• HER2-positive early-stage breast cancer (neoadjuvant setting): Used in combination with trastuzumab and chemotherapy before surgery to reduce tumor size.
• HER2-positive early-stage breast cancer (adjuvant setting): Used in combination with trastuzumab and chemotherapy after surgery to reduce the risk of cancer recurrence.

• Perjeta 420mg/14ml works by binding to the extracellular dimerization domain of the HER2 protein. This action blocks the ligand-dependent heterodimerization of HER2 with other HER family members, inhibiting intracellular signaling pathways such as the mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase (PI3K) pathways. This inhibition results in cell growth arrest and apoptosis, thereby slowing the proliferation of cancer cells.

Perjeta 420mg/14ml can cause various side effects, ranging from common to serious. Patients should be aware of these potential reactions and consult their healthcare provider if they experience any severe symptoms.

Common Side Effects

• Diarrhea: Frequent bowel movements or loose stools.
• Alopecia: Hair loss or thinning.
• Nausea: Feeling sick to the stomach.
• Fatigue: Extreme tiredness or lack of energy.
• Neutropenia: Low white blood cell count, increasing the risk of infection.
• Vomiting: Expelling stomach contents through the mouth.

Serious or Rare Side Effects

• Left ventricular dysfunction: Decreased heart function, which can lead to heart failure.
• Infusion-related reactions: Allergic reactions during or after the infusion, which can be severe.
• Hypersensitivity reactions: Severe allergic reactions, including anaphylaxis.
• Febrile neutropenia: High fever accompanied by a low white blood cell count.

Perjeta 420mg/14ml should be used with caution and under the supervision of a healthcare professional. Certain precautions and warnings should be followed to ensure safe and effective treatment.

• Administration: Should be administered by trained medical staff in a clinical setting.
• Monitoring: Regular monitoring of left ventricular function is recommended, especially in patients with a history of heart disease.
• Hypersensitivity: Patients with known hypersensitivity to pertuzumab or any of its excipients should avoid this medication.
• Pregnancy: Should be avoided during pregnancy unless the potential benefit outweighs the risk to the fetus.
• Storage: Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Perjeta 420mg/14ml may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. Patients should inform their healthcare provider about all medications they are taking.

Major Interactions (Avoid)

• Anthracyclines: Concurrent use with anthracyclines may increase the risk of cardiac toxicity.
• Trastuzumab: Concurrent use with trastuzumab may increase the risk of left ventricular dysfunction.

Moderate Interactions (Monitor Closely)

• Chemotherapy agents: Close monitoring is required when used in combination with other chemotherapy agents to manage potential side effects.
• Immunosuppressants: May increase the risk of infections when used with other immunosuppressant medications.